Rationale: Arteriogenesis is the process of formation of arterial conduits. Its promotion is an attractive therapeutic strategy in occlusive atherosclerotic diseases. Despite the functional and clinical importance of arteriogenesis, the biology of the process is poorly understood. Synectin, a gene previously implicated in the regulation of vascular endothelial cell growth factor signaling, offers a unique opportunity to determine relative contributions of various cell types to arteriogenesis.
A rteriogenesis, the process of formation of arterial conduits, is a promising therapeutic approach for the treatment of several ischemic vascular diseases. Yet, its biology remains poorly understood. New vasculature can form via 3 distinct processes: vasculogenesis, angiogenesis, and arteriogenesis. Vasculogenesis refers to the formation of the primitive vascular plexus from vascular progenitor cells during embryonic development. Angiogenesis is the process of new capillary formation that occurs by sprouting or longitudinal splitting (intussusception) of existing vessels. 1, 2 Finally, arteriogenesis refers to the development of larger vessels such as arterioles and arteries. 3 Collateral formation represents a specific case of arteriogenesis. By definition, collateral vessels provide artery-to-artery connections and are thought to play a protective role by providing alternative routes to blood flow. 4, 5 
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Although angiogenesis is largely driven by vascular endothelial growth factor (VEGF) production in response to hypoxia 6 or inflammation, 2 little is known about factors controlling arteriogenesis, in general, and collateral formation, in particular. In adult tissues, arteriogenesis can occur at sites of arterial occlusion where ischemia is not prominent and is thought to be triggered by hemodynamic factors, such as changes in shear stress forces sensed by endothelial cells (ECs). 7, 8 How that happens is the subject of considerable controversy. One possible scenario is that arteriogenesis is the result of remodeling of preexisting collaterals. The existence of small collaterals that expand on occlusion of the main arterial trunk has been clearly described, both in animals 9 and in humans, 10 and the ability to restore compromised tissue perfusion has been linked to the extent of preexisting collateral circulation. 11 Alternatively, adult arteriogenesis has been described as a de novo process that occurs by the expansion and arterialization of the capillary bed. [12] [13] [14] In this scenario, the ability of ECs to proliferate and secrete growth factors, is crucial for new vascular network development and subsequent arterialization via recruitment of mural cells. One piece of evidence strongly in favor of this hypothesis is the extent of new arterial growth observed by micro-computed tomographic (mCT) angiography after a large artery occlusion. 15 This is highly unlikely to arise solely from preexisting collaterals.
Studies during the past decade have identified several growth factors, including platelet-derived growth factor (PDGF) fibroblast growth factors, and VEGF, [16] [17] [18] [19] [20] cytokines such as monocyte chemotactic protein 1, 21, 22 peptides such as neuropeptide Y, 23 and master regulators such as hypoxia-inducible factor-1α, 24, 25 hypoxia-inducible factor-2α, 26 and PR39 27, 28 that can promote arteriogenesis. Of these, VEGF-A seems to play the central role. In particular, experimental studies have demonstrated that collateral growth is prevented by anti-VEGF-A--neutralizing antibodies, 5 VEGF receptor (VEGFR) inhibitors, 29 and soluble VEGFR traps, 30 whereas genetic approaches further demonstrated the requirement for VEGF-A expression for collateral development in healthy tissue. 17 Disruption of VEGF signaling as a result of impairment of VEGFR2 trafficking has also been shown to result in decreased arteriogenesis. [31] [32] [33] Although the role of VEGF-A in arteriogenesis is well-established, its cellular site of action remains uncertain. In this study, we set out to address the cellular underpinnings of VEGFdependent arteriogenesis. To this end, we have taken advantage of the recent identification of an arterial morphogenetic defect associated with a global deletion of synectin by our laboratory. 31, 32 Synectin is a widely expressed single PDZ domain protein that interacts with a variety of plasma membrane and cytoplasmic molecules 31, 34, 35 to control intracellular signaling. Homozygous disruption of synectin in mice or a knockdown of its expression in zebrafish results in a selective reduction of arterial morphogenesis, including decreased branching and reduced size and diameter of the arterial vasculature. 31 Synectin-null ECs have reduced responsiveness to VEGF stimulation 31, 32 and decreased activation of ERK, whereas their responses to other growth factors such as fibroblast growth factors and insulin-like growth factor are normal. 32 In addition, synectin-null mice display downregulation of PDGF expression in the endothelium, likely accounting for the loss of vascular smooth muscle cell (SMC) coverage of smaller blood vessels observed in these settings. 36 This gene, therefore, offers a unique ability to help determine relative contributions of various cell types to arteriogenesis.
To study that problem, we generated a mouse line with a floxed synectin gene knocked-in into the synectin (gipc1) locus and crossbred it with endothelial (Tie2, Cdh5, and Pdgfb) and smooth muscle myosin heavy chain-specific Cre mouse lines to produce EC-specific and SMC-specific deletions, respectively. We found that ablation of synectin expression in EC but not SMC mimicked the arterial phenotype of global synectin-null mutants, 31 thereby implicating endothelium as the key cell type regulating arteriogenesis.
Methods
Full methods are described in the online-only Data Supplement.
Mice
Mice homozygous for a conditional allele of synectin (gipc1) were generated by flanking exon 2 with loxP sites. 
Primary SMC and EC Isolation and Culture
Primary SMCs were isolated from dorsal aorta, as previously described, 41 with minor modifications. Primary ECs were isolated from the heart and lung of adult mice using a previously described protocol.
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Hindlimb Ischemia Model
The hindlimb ischemia model was performed as previously described in our laboratory. 28, 31 Laser Doppler flow imaging was performed using a Moor Infrared Laser Doppler Imager (Moor Instruments) at 36.5°C to 37.5°C under isoflurane anesthesia.
Micro-CT Angiography
mCT of the cardiac, renal, and hindlimb vasculature was performed by injecting 0.7 mL bismuth contrast solution in the descending aorta, and the vasculature was imaged and quantified as described previously. 28, 31, 42 
Spinotrapezius Assay
Spinotrapezius muscles (both left and right) from euthanized mice were stripped of fascia and dissected as described previously. 14, 43 Quantifications of vessel diameters and collateral arcades were performed using ImageJ software. 44 
Retina Analysis
The eyes were harvested at postnatal day 5 and postnatal day 17 and processed as described in the online-only Data Supplement.
In Vivo Matrigel Assay
The Matrigel was premixed with heparin (5 U) with or without VEGF-A 165 (100 ng/mL) and injected subcutaneously. Seven days later, the plugs were recovered from the euthanized mice, embedded in optimum cutting temperature compound, cryosectioned in 10-μm sections, and stained with anti-CD31 antibody.
Wound Healing Assay
Wound healing assays were performed by creating 6-mm punch wounds in the skin of the back of 12-week to 14-week-old male mice. The healing process was analyzed over time. 45 
Results
Generation of gipc1 Floxed Mice and Smooth Muscle and Endothelial Knockouts
To evaluate the specific contributions of ECs and SMCs to arteriogenesis, we generated mice carrying a floxed synectin allele inserted into the endogenous gipc1 gene locus. The targeting strategy ( Figure 1A ) resulted in the creation of a gipc1 allele, with loxP sites flanking a neomycin resistance cassette and exon 2 of the gipc1 gene. The neomycin resistance gene was subsequently 
. D, Decreased synectin protein levels in ECs isolated from Syn ECKO mice compared with Syn WT mice. E, Western blotting of total cell lysates isolated from heart ECs. Confluent, serum-starved ECs were stimulated for the times indicated with 50 ng/mL vascular endothelial growth factor (VEGF)-A 165 . Note reduced P-ERK and phosphorylation of VEGFR2 Y1175 site (P-VEGFR2 Y1175) in synectin-null endothelial cells. ECKO indicates endothelial cell conditional knockout; P-VEGFR2, phosphorylated VEGFR2; SM-α-actin, SMC α-actin; SMKO, smooth muscle cell conditional knockout; Syn, synectin; T-ERK, total ERK; T-VEGFR2, total VEGFR2; VE-cadh, vascular endothelial cadherin; and WT, wild-type.
removed using flp-mediated recombination. Screening of the progeny confirmed the presence of the floxed allele ( Figure 1B) .
To ablate synectin expression in SMCs, gipc1 fl/fl mice were crossed with smooth muscle myosin heavy chain-Cre strain, and the progeny were bred to produce mice homozygous for the loss of smooth muscle synectin expression (Syn SMKO ). Genotyping of litters containing Syn SMKO mice (smooth muscle myosin heavy chain-Cre;Syn FF ) revealed the presence of all genotypes with the expected Mendelian frequency.
Carotid arteries and aorta from Syn SMKO mice had markedly lower mRNA levels of synectin than littermate controls ( Figure 2A ). Western blot analysis of synectin expression in primary SMCs and ECs, isolated from these mice, confirmed nearly complete loss of synectin expression in SMCs but not in ECs ( Figure 2B ). Stimulation of Syn SMKO SMCs with PDGF-BB, one of the key growth factors regulating SMC migration and proliferation, revealed no differences in ERK activation compared with control SMCs, demonstrating that synectin expression in smooth muscle is not required for a normal response to PDGF-BB stimulation ( Figure 2C ). These observations are in line with what has been previously shown in SMCs from global synectin-null mice. 36 To ablate synectin in EC, homozygous floxed synectin mice were crossed with the Tie2-Cre mouse line and the progeny were bred for endothelial-specific knockout of synectin (Syn ECKO ). Western blot analysis of primary heart and lung ECs isolated from these mice confirmed a marked reduction in synectin expression in these cells ( Figure 2D ). Previous studies from our laboratory have demonstrated reduced responsiveness to VEGF stimulation of synectin-null arterial EC isolated from synectin global knockout mice. 31, 32 To confirm that EC-selective disruption of synectin resulted in the same phenotype at the cellular level, we examined VEGF signaling in ECs isolated from Syn ECKO mice. Analysis of VEGFR2 activation after stimulation with VEGF-A demonstrates an expected reduction in Y 1175 site phosphorylation and a decrease in ERK1/2 activation ( Figure 2E ).
Impaired Arterial Development in Syn ECKO But Not in Syn SMKO Mice
To assess the impact of EC and SMC synectin deletion in the arterial development, we performed mCT angiography of the heart ( Figure 3A ) and renal vasculature ( Figure 3B ) of Syn SMKO , Syn ECKO , and littermate control mice as described previously.
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Figure 3. Developmental arteriogenesis defects are present in Syn ECKO but not in Syn SMKO mice. Representative reconstructed microcomputed tomographic (mCT) images of whole heart (A) and kidney (B) arterial vasculature (16- Figure 3C ). This reduction in the number of smaller-caliber arteries in Syn ECKO mice is similar to that observed in the global synectin knockout. 31 To our surprise, we found aneurysmal dilations of distal coronary arteries ( Figure 3D , arrowheads) and even frank tubular aneurysms in Syn ECKO mice (arrow) that were not previously seen in global synectin-null mice.
To gain a better understanding of arterial microcirculation changes associated with an endothelial-specific synectin knockout, we examined vascular networks in the spinotrapezius muscle.
14 Because of its thinness (≈150 µm), the entire vascular network of the muscle can be imaged in whole-mount at micron-level resolution ( Figure 4A ). The muscle is fed by multiple arterioles, notably lateral and caudal feed vessels ( Figure 4A , red arrowheads) that are connected by an arteriolar arcade network providing multiple collateral pathways for blood flow. 14, 46 In wild-type mice, the collateral networks have a ramified arcade structure with multiple arteriole linkage, whereas in Syn ECKO mice the network has a dendritic structure with smaller arteries and fewer arteriolar-level connections ( Figure 4A (Figure 4B ), thus confirming spinotrapezius angiography and coronary mCT observations. In addition, the number of arteriolar arcades (collateral arteries) is significantly lower in Syn ECKO compared with Syn SMKO or littermate control mice ( Figure 4C ).
Postnatal Arteriogenesis Defects in Synectin Endothelial Knockout Mice
To investigate the effect of SMC-specific and EC-specific synectin knockout on arterial morphogenesis in adult tissues, we next analyzed arteriogenesis in Syn SMKO and Syn ECKO mice using a hindlimb ischemia model. In this model, arteriogenesis is induced by ligation and excision of a segment of the common femoral artery of 10-12 week old mice. 28 After artery ligation, blood flow in the distal limb is assessed by a deep-penetrating laser Doppler and expressed as a ratio of flow in the foot of operated to nonmanipulated limb. Immediately after surgery, there was a dramatic but equal reduction in perfusion in all 3 groups ( Figure 5A and 5D ). Blood flow in the distal limb of control and Syn SMKO mice recovered to the same extent during the next 2 weeks ( Figure 5A ). Because growth of new arterial vasculature is the principal event responsible for blood flow restoration in this model, we next performed mCT analysis to visualize and quantify the extent of hindlimb vasculature 14 days after surgery. In agreement with the finding of unimpaired distal blood flow recovery, mCT of the arterial vasculature confirmed comparable arteriogenesis in Syn SMKO and wild-type mice ( Figure 5B and 5C). Interestingly, there was a nonsignificant trend toward larger artery sizes in Syn SMKO but not in control mice ( Figure 5C ). However, blood flow recovery was significantly impaired in Syn ECKO mice, which was apparent 1 week after surgery ( Figure 5D ) and was similar to that previously observed in synectin global knockout mice. As expected, mCT analysis of the arterial circulation demonstrated a significant reduction in the number of smaller arterial vessels in the tight muscle ( Figure 5E and 5F).
Inducible Ablation of Synectin Expression in ECs
Because the Tie2 promoter has been shown to activate Cre expression not only in endothelial lineage but also in hematopoietic lineages during development, 47 this may result in deletion of synectin expression in monocytes and monocytederived macrophages. These cells play an important role in postnatal arteriogenesis, particularly in the hindlimb ischemia model. 48, 49 To exclude the possibility that decreased synectin expression in cells other than the endothelium was responsible for the impaired arteriogenesis after common femoral artery ligation in adult mice, we used Cdh5-CreERT2 transgenic mouse line. 39 Unlike Tie2, Cdh5 expression is much more restricted to the endothelium, and little, if any, expression occurs in cells of hematopoietic lineages postnatally.
Analysis of the arteriogenesis in the hindlimb ischemia model was performed in 10-week-old sex-matched induced endothelial synectin knockout (iEC-SynKO) mice and controls (n=6/group). Similar to Syn ECKO (Tie2-Cre;Syn FF ), iEC-Syn-KO (Cdh5-CreERT2;Syn FF ) mice demonstrated a significant decline in blood flow recovery after the common femoral artery ligation ( Figure 6A and 6B). Quantitative polymerase chain reaction analysis of synectin mRNA expression in lung ECs isolated from iEC-SynKO mice (n=3) showed markedly decreased expression compared with controls ( Figure 6C) .
Analysis of the spinotrapezius vascular networks in iECSynKO mice again demonstrated a significant reduction in the number of collateral arcade structures compared with control littermates (Figure 6D and 6E) . In addition, diameters of the input arterioles were significantly less in iEC-SynKO mice compared with control littermates (Figure 6E To address the effect of synectin ablation on adult angiogenesis, we first used a puncture wound model in 
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Cdh5Cre-ERT2;Syn FF mice (iEC-SynKO). The rate of wound healing in this model reflects the underlying angiogenesis, and angiogenic defects impair the rate of wound closure. 45 Visual inspection and quantitative analysis demonstrated no difference in wound closure rate between synectin deletants and littermate controls ( Figure 8A and 8B) . Finally, iEC-SynKO mice were used for an in vivo Matrigel assay. Analysis of Matrigel plugs impregnated with VEGF extracted from control and iECSynKO mice demonstrated no differences ( Figure 8C and 8D ).
Discussion
The results of this study demonstrate that synectin modulates developmental and adult arteriogenesis in an EC-autonomous fashion. In addition, we demonstrate that endothelial synectin is not required for adult angiogenesis. Specifically, synectin knockout in EC results in several developmental and adult arterial morphogenetic defects, including smaller size of the arterial tree, reduced numbers of arterial branches and collaterals, and impaired blood flow recovery after common femoral artery ligation. At the same time, SMC-specific deletion of synectin does not affect the size of the arterial tree, the number of collaterals, or blood flow recovery in adult animals.
We focused on cell type-specific synectin knockout because of its critical role in the regulation of VEGF signaling, which is central to the process of arteriogenesis. 50 Synectin accomplishes this by facilitating, in complex with myosin VI, trafficking of newly endocytosed VEGFR2-containing vesicles away from the plasma membrane to EEA1 + endosomes. This allows prolonged phosphorylation of the VEGFR2 Y 1175 site involved in the activation of PLCγ/ERK signaling, which is essential for normal ) and control mice subjected to common femoral artery ligation. B, Laser Doppler analysis of blood flow recovery after surgery expressed as a ratio of flow in ischemic (R) to normal (L) foot (R/L ratio) at various time points. Note a significant decrease in flow recovery in iEC-SynKO mice at 7 and 14 days compared with controls. Mean±SD, *P≤0.05, **P≤0.01 (n=6 per group). C, Decreased synectin RNA levels in lung endothelial cells (ECs) from iEC-SynKO mice compared with control. D, Image of the caudal half of the mouse spinotrapezius. Staining for smooth muscle α-actin has been pseudocolored to indicate arteries (red) and veins (blue). Scale bar, 500 µm. Input arterioles entering the muscle are denoted by red arrowheads. E, Quantitative analysis of the number of collateral arcades in the spinotrapezius muscle and diameter of the input arterioles as they enter the muscle in iEC-SynKO and wild-type (WT) mice (n=3 each); P≤0.05, 2-tailed t test. Syn indicates synectin; and VE-cadh, vascular endothelial cadherin.
arteriogenesis. 51 Although this mechanism has been shown to operate in ECs, given the ubiquitous nature of synectin expression and the central role of synectin/myosin VI complex in trafficking intracellular vesicles formed during clathrin-dependent endocytosis, 52 it is possible that the same holds true in all cells expressing VEGF receptors.
To address the cell-autonomous effects of synectin, we used SMC-specific and EC-specific Cre driver lines crossed with floxed synectin knockin mice to generate synectin deletions in these cell types. Analysis of arterial circulation in hearts, kidneys, and skeletal muscles of EC-specific synectin mice demonstrated reduced numbers of arteries, reduced branching, and decreased arterial diameter, whereas no significant differences in these parameters were seen in smooth muscle-specific synectin knockout mice. These results were confirmed by analysis of arteriolar networks in the spinotrapezius muscle, where we also observed reduced arteriolar size and fewer artery-to-artery connections in EC-specific but not in SMC-specific synectin knockouts. Adult arteriogenesis, assessed as the ability to form new arteries in response to common femoral artery ligation, was also abnormal in Syn ECKO but not Syn SMKO mice. This was demonstrated both by the impaired blood flow recovery to the distal limb in Syn ECKO mice and by the reduced numbers of small arteries forming above the knee.
All of these studies were performed using Tie2-Cre driver line, which, in addition to ECs, is also expressed in a small number of hematopoietic precursor cells that differentiate into several cell types, including monocytes/macrophages that play an important role in arterial morphogenesis. To exclude the possibility that Tie2 expression in cells other than ECs was responsible for the observed arteriogenesis defects, floxed synectin mice were also crossed with Cdh5-CreERT2 transgenic mouse line that has a much more endothelium-restricted expression. Activation of Cdh5-driven Cre (iEC-SynKO), either during development or postnatally, reproduced the arterial morphogenesis defects observed in global synectin-null and Syn ECKO mice, whereas angiogenesis (developmental and adult) was not affected.
As already alluded to, synectin regulates VEGFR2 signaling and, specifically, activation of ERK by ensuring, in partnership with neuropilin 1 and myosin VI, a rapid transit of VEGFR2 through the phosphatase zone, thus preventing its deactivation by phosphotyrosine phosphatase 1b. 33, 53 Any reduction in endothelial ERK activation, as seen in synectin or myosin VI knockouts 31, 32 or in Nrp1 cyto knockin mice, 33 results in arterial morphogenic defects. Interestingly, in all of these cases, as well as in the present study of endothelial-specific synectin deletion, angiogenesis remains normal.
The availability of synectin floxed mice has allowed us to address another critical point in arteriogenesis biology, namely the identification of the cell type critical to this process. The fact that endothelial disruption of synectin expression impairs all forms of arterial morphogenesis-developmental and adult as well as collateral development-clearly states that endothelial activation of ERK signaling, a process that synectin regulates, is central to arteriogenesis.
The nature of arteriogenic process, especially in adult tissues, has long remained poorly understood. The 2 most frequently advanced hypotheses are the remodeling of preexisting arterial vasculature into larger size arteries and de novo growth of new arteries. The remodeling of preexisting arteries (usually invoked in terms of collateral development, a special case of arteriogenesis) implies the expansion of the lumen and increased size of the vessel wall, a process that requires SMC proliferation. 19, 54 In contrast, the de novo growth of new arteries suggests formation of new arterial conduits via arterialization of the capillary network. Such a process would be expected to be heavily dependent on EC proliferation because it requires capillary bed expansion. [12] [13] [14] Defective arteriogenesis in EC-specific synectin mutants strongly argues for the second hypothesis. The decreased VEGF responsiveness of synectin-deficient endothelium likely affects arteriogenesis by affecting 2 critical processes: formation and expansion of vascular lumen and recruitment of mural cells. With regard to the former, it is interesting to note that in all cases of reduced endothelial ERK activation, [31] [32] [33] including the present study of EC-specific synectin deletion, arterial diameter for comparable arteries (eg, proximal coronary versus proximal coronary) is smaller than in control mice. Furthermore, in vitro assay demonstrates that reduced ERK activation leads to reduced lumen formation. 33 At the same time, excessive endothelial activation of ERK signaling leads to the formation of larger than normal diameter arteries. 55 With regard to the latter, decreased endothelial synectin expression leads to reduced secretion of PDGF-BB, 36 the growth factor most associated with mural cell recruitment. 56, 57 Combined, these 2 defects would lead to decreased capillary bed arterialization, a process that requires an increase in capillary lumen diameter and mural cell recruitment.
The role of synectin and endothelial VEGF resistance is supported by 2 other studies: (1) rescue of synectin-null arteriogenic defect by treatment with phosphotyrosine phosphatase 1b inhibitor, which abolishes the delayed VEGFR2 trafficking, thereby activating VEGR2/ERK signaling; 31, 32 and (2) rescue of synectin-null and hypercholesterolemic mice (which are VEGF-resistant) by treatment with a phosphoinositol-3-kinase inhibitor, which activates ERK signaling independently of VEGFR2. 58 Although these studies were performed with global knockouts or globally impaired mice (hypercholesterolemia), the present study, with a selective endothelial knockout, closes the loop. Impaired VEGF signaling only in ECs is enough to affect arteriogenesis. This supports the de novo arteriogenesis rather than remodeling of preexisting collaterals as the dominant process.
In addition, we used a severe model of hindlimb ischemia that effectively eliminates any protective role of preexisting collaterals. In fact, measurements of blood flow immediately after surgery demonstrate no difference between wild-type and synectin EC-null mice (iEC-SynKO, Syn ECKO ), supporting this argument. Also, the difference in blood flow recovery does not appear until day 7, a time course that is consistent with capillary bed arterialization that is largely endothelium-driven, whereas preexisting collateral growth typically peaks by day 3. 28, 59 Therefore, all subsequent differences are largely because of de novo arteriogenesis, not because of preexisting collateral remodeling.
More broadly, endothelial resistance to VEGF signaling, whether because of defective VEGFR2 trafficking or because of other mechanisms, would be expected to result in arteriogenic defects. This concept is supported by many previous studies that addressed the role of VEGF signaling in the process of collateral formation. 5, 17, 29, 30 In conclusion, understanding how new arteries form in response to ischemia is crucial to developing effective treatments in ischemic vascular diseases. This study identifies ECs and endothelial VEGF responsiveness as key elements in growth and development of new arteries. We suggest that the focus of future therapeutics efforts should be on overcoming endothelial VEGF resistance frequently observed in patients with underlying pathologies such as atherosclerosis 28 and diabetes mellitus 60, 61 and that simply providing additional VEGF either directly or via stimulation of mononuclear cell recruitment is unlikely to result in a therapeutic benefit.
